-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network News on August 4th.
The relevant evidence of clinical comprehensive evaluation will become evidence that medical institutions refuse to enter certain drugs into this institution.
However, this guideline is not a departmental regulation and is not legally mandatory
.
However, the use of the evidence information generated by this guide is of reference value
.
The relevant evidence of clinical comprehensive evaluation will become evidence that medical institutions refuse to enter certain drugs into this institution.
However, this guideline is not a departmental regulation and is not legally mandatory
.
However, the use of the evidence information generated by this guide is of reference value
.
On July 28, the Department of Drug Policy and Essential Drug System of the National Health Commission issued the "Guidelines for the Management of Comprehensive Clinical Evaluation of Drugs (Trial Version in 2021)", which is mainly used by national and provincial health departments to select basic drugs for disease prevention and control, and to formulate major drugs.
Decision-making purposes such as basic drug policy for disease prevention and treatment and strengthening drug supply management
.
Decision-making purposes such as basic drug policy for disease prevention and treatment and strengthening drug supply management
.
In the third chapter "Evidence Evaluation and Application" of the guide, it is pointed out that the scope of clinical comprehensive evaluation evidence application of regional and medical and health institutions is:
(1) Drug procurement and supply guarantee for medical and health institutions ;
(2) Promote the selection of drug catalogs for medical and health institutions and the linkage of drug catalogs for medical and health institutions at higher and lower levels to improve the level of pharmaceutical services and safe and rational drug use;
(3) Control unreasonable drug expenditures, improve the efficiency of health resource allocation, and optimize the structure of drug use;
(4) Provide a reference for improving the national drug policy
.
.
It can be seen that the guidelines will further affect the drug market access based on the national medical insurance catalogue and the centralized drug procurement policy
.
.
1.
The main links that have an impact on drug market access
The main links that have an impact on drug market access
The national medical insurance catalog and the national centralized procurement policy determine whether it can enter the national public medical institution market, and the provincial-level drug centralized procurement policy determines whether it can enter the provincial public medical institution market
.
The relevant evidence of the clinical comprehensive evaluation will become the evidence that the medical and health institution refuses certain drugs to enter the medical and health institution
.
This may be the main reason why the guidelines emphasize the confidentiality of information related to comprehensive clinical evaluation
.
.
The relevant evidence of the clinical comprehensive evaluation will become the evidence that the medical and health institution refuses certain drugs to enter the medical and health institution
.
This may be the main reason why the guidelines emphasize the confidentiality of information related to comprehensive clinical evaluation
.
2.
The legal effect of the impact on drug market access
The legal effect of the impact on drug market access
The "Guidelines for the Management of Comprehensive Clinical Evaluation of Drugs (Trial Version in 2021)" is a normative document issued by the Department of Drug Policy and Essential Drug System of the National Health Commission.
It does not belong to departmental regulations and is not legally mandatory
.
That is to say, the evidence information generated by the use of this guide has reference value, but it cannot be used to force drugs to withdraw from the drug market of a hospital based on this information
.
It does not belong to departmental regulations and is not legally mandatory
.
That is to say, the evidence information generated by the use of this guide has reference value, but it cannot be used to force drugs to withdraw from the drug market of a hospital based on this information
.
It is expected that medical and health institutions will also be very cautious when using comprehensive clinical evaluation of evidence information
.
However, it is certain that the clinical comprehensive evaluation evidence information will be the important reference information for the hospital to decide whether the drug can enter the hospital
.
.
However, it is certain that the clinical comprehensive evaluation evidence information will be the important reference information for the hospital to decide whether the drug can enter the hospital
.
3.
The main factors affecting the access to the pharmaceutical market
The main factors affecting the access to the pharmaceutical market
Compared with the provisions of the medical insurance catalog access policy documents, the evaluation dimensions of clinical comprehensive evaluation are more diverse, including safety, effectiveness, economy, innovation, suitability, and accessibility
.
Compared with single-dimensional evaluation, multi-criteria decision-making is the leading international health technology evaluation method
.
However, the difficulty is how to integrate multiple dimensions and what decision-making criteria are combined to arrive at a decision-making conclusion
.
.
Compared with single-dimensional evaluation, multi-criteria decision-making is the leading international health technology evaluation method
.
However, the difficulty is how to integrate multiple dimensions and what decision-making criteria are combined to arrive at a decision-making conclusion
.
One method is to set different weights for the six dimensions through expert consultation, and finally form a summary score to rank the drugs for clinical comprehensive evaluation, and then draw the conclusion of hospital market access based on a certain decision criterion
.
In the process of this operation, the transparency of weights and decision-making standards will determine the fairness and credibility of hospital drug market access, and even affect the supply of hospital drugs in the future
.
.
In the process of this operation, the transparency of weights and decision-making standards will determine the fairness and credibility of hospital drug market access, and even affect the supply of hospital drugs in the future
.
In short, comprehensive clinical evaluation is very important for medical and health institutions and pharmaceutical companies .
The transparency of relevant evidence production, evaluation process, and decision-making process will determine the effectiveness of comprehensive clinical evaluation information for hospital drug market access.
However, understanding comprehensive clinical evaluation is important for pharmaceutical companies.
Practitioners are very important, and they need to accumulate knowledge in relevant aspects early and assess the impact on their own drug market access
.
The transparency of relevant evidence production, evaluation process, and decision-making process will determine the effectiveness of comprehensive clinical evaluation information for hospital drug market access.
However, understanding comprehensive clinical evaluation is important for pharmaceutical companies.
Practitioners are very important, and they need to accumulate knowledge in relevant aspects early and assess the impact on their own drug market access
.
Medical Network News on August 4th.
The relevant evidence of clinical comprehensive evaluation will become evidence that medical institutions refuse to enter certain drugs into this institution.
However, this guideline is not a departmental regulation and is not legally mandatory
.
However, the use of the evidence information generated by this guide is of reference value
.
The relevant evidence of clinical comprehensive evaluation will become evidence that medical institutions refuse to enter certain drugs into this institution.
However, this guideline is not a departmental regulation and is not legally mandatory
.
However, the use of the evidence information generated by this guide is of reference value
.
On July 28, the Department of Drug Policy and Essential Drug System of the National Health Commission issued the "Guidelines for the Management of Comprehensive Clinical Evaluation of Drugs (Trial Version in 2021)", which is mainly used by national and provincial health departments to select basic drugs for disease prevention and control, and to formulate major drugs.
Decision-making purposes such as basic drug policy for disease prevention and treatment and strengthening drug supply management
.
Decision-making purposes such as basic drug policy for disease prevention and treatment and strengthening drug supply management
.
In the third chapter "Evidence Evaluation and Application" of the guide, it is pointed out that the scope of clinical comprehensive evaluation evidence application of regional and medical and health institutions is:
(1) Drug procurement and supply guarantee for medical and health institutions ;
(2) Promote the selection of drug catalogs for medical and health institutions and the linkage of drug catalogs for medical and health institutions at higher and lower levels to improve the level of pharmaceutical services and safe and rational drug use;
(3) Control unreasonable drug expenditures, improve the efficiency of health resource allocation, and optimize the structure of drug use;
(4) Provide a reference for improving the national drug policy
.
.
It can be seen that the guidelines will further affect the drug market access based on the national medical insurance catalogue and the centralized drug procurement policy
.
.
1.
The main links that have an impact on drug market access
The main links that have an impact on drug market access
The national medical insurance catalog and the national centralized procurement policy determine whether it can enter the national public medical institution market, and the provincial-level drug centralized procurement policy determines whether it can enter the provincial public medical institution market
.
The relevant evidence of the clinical comprehensive evaluation will become the evidence that the medical and health institution refuses certain drugs to enter the medical and health institution
.
This may be the main reason why the guidelines emphasize the confidentiality of information related to comprehensive clinical evaluation
.
.
The relevant evidence of the clinical comprehensive evaluation will become the evidence that the medical and health institution refuses certain drugs to enter the medical and health institution
.
This may be the main reason why the guidelines emphasize the confidentiality of information related to comprehensive clinical evaluation
.
2.
The legal effect of the impact on drug market access
The legal effect of the impact on drug market access
The "Guidelines for the Management of Comprehensive Clinical Evaluation of Drugs (Trial Version in 2021)" is a normative document issued by the Department of Drug Policy and Essential Drug System of the National Health Commission.
It does not belong to departmental regulations and is not legally mandatory
.
That is to say, the evidence information generated by the use of this guide has reference value, but it cannot be used to force drugs to withdraw from the drug market of a hospital based on this information
.
It does not belong to departmental regulations and is not legally mandatory
.
That is to say, the evidence information generated by the use of this guide has reference value, but it cannot be used to force drugs to withdraw from the drug market of a hospital based on this information
.
It is expected that medical and health institutions will also be very cautious when using comprehensive clinical evaluation of evidence information
.
However, it is certain that the clinical comprehensive evaluation evidence information will be the important reference information for the hospital to decide whether the drug can enter the hospital
.
.
However, it is certain that the clinical comprehensive evaluation evidence information will be the important reference information for the hospital to decide whether the drug can enter the hospital
.
3.
The main factors affecting the access to the pharmaceutical market
The main factors affecting the access to the pharmaceutical market
Compared with the provisions of the medical insurance catalog access policy documents, the evaluation dimensions of clinical comprehensive evaluation are more diverse, including safety, effectiveness, economy, innovation, suitability, and accessibility
.
Compared with single-dimensional evaluation, multi-criteria decision-making is the leading international health technology evaluation method
.
However, the difficulty is how to integrate multiple dimensions and what decision-making criteria are combined to arrive at a decision-making conclusion
.
.
Compared with single-dimensional evaluation, multi-criteria decision-making is the leading international health technology evaluation method
.
However, the difficulty is how to integrate multiple dimensions and what decision-making criteria are combined to arrive at a decision-making conclusion
.
One method is to set different weights for the six dimensions through expert consultation, and finally form a summary score to rank the drugs for clinical comprehensive evaluation, and then draw the conclusion of hospital market access based on a certain decision criterion
.
In the process of this operation, the transparency of weights and decision-making standards will determine the fairness and credibility of hospital drug market access, and even affect the supply of hospital drugs in the future
.
.
In the process of this operation, the transparency of weights and decision-making standards will determine the fairness and credibility of hospital drug market access, and even affect the supply of hospital drugs in the future
.
In short, comprehensive clinical evaluation is very important for medical and health institutions and pharmaceutical companies .
The transparency of relevant evidence production, evaluation process, and decision-making process will determine the effectiveness of comprehensive clinical evaluation information for hospital drug market access.
However, understanding comprehensive clinical evaluation is important for pharmaceutical companies.
Practitioners are very important, and they need to accumulate knowledge in relevant aspects early and assess the impact on their own drug market access
.
The transparency of relevant evidence production, evaluation process, and decision-making process will determine the effectiveness of comprehensive clinical evaluation information for hospital drug market access.
However, understanding comprehensive clinical evaluation is important for pharmaceutical companies.
Practitioners are very important, and they need to accumulate knowledge in relevant aspects early and assess the impact on their own drug market access
.
Medical Network News on August 4th.
The relevant evidence of clinical comprehensive evaluation will become evidence that medical institutions refuse to enter certain drugs into this institution.
However, this guideline is not a departmental regulation and is not legally mandatory
.
However, the use of the evidence information generated by this guide is of reference value
.
The relevant evidence of clinical comprehensive evaluation will become evidence that medical institutions refuse to enter certain drugs into this institution.
However, this guideline is not a departmental regulation and is not legally mandatory
.
However, the use of the evidence information generated by this guide is of reference value
.
On July 28, the Department of Drug Policy and Essential Drug System of the National Health Commission issued the "Guidelines for the Management of Comprehensive Clinical Evaluation of Drugs (Trial Version in 2021)", which is mainly used by national and provincial health departments to select basic drugs for disease prevention and control, and to formulate major drugs.
Decision-making purposes such as basic drug policy for disease prevention and treatment and strengthening drug supply management
.
Healthy, healthy, healthyDecision-making purposes such as basic drug policy for disease prevention and treatment and strengthening drug supply management
.
In the third chapter "Evidence Evaluation and Application" of the guide, it is pointed out that the scope of clinical comprehensive evaluation evidence application of regional and medical and health institutions is:
(1) Drug procurement and supply guarantee for medical and health institutions ;
Drug Purchasing Drugs and Drug Purchasing Procurement (2) Promote the selection of drug catalogs for medical and health institutions and the linkage of drug catalogs for medical and health institutions at higher and lower levels to improve the level of pharmaceutical services and safe and rational drug use;
(3) Control unreasonable drug expenditures, improve the efficiency of health resource allocation, and optimize the structure of drug use;
(4) Provide a reference for improving the national drug policy
.
.
It can be seen that the guidelines will further affect the drug market access based on the national medical insurance catalogue and the centralized drug procurement policy
.
.
1.
The main links that have an impact on drug market access
1. The main links that have an impact on drug market access
The main links that have an impact on drug market access
The national medical insurance catalog and the national centralized procurement policy determine whether it can enter the national public medical institution market, and the provincial-level drug centralized procurement policy determines whether it can enter the provincial public medical institution market
.
The relevant evidence of the clinical comprehensive evaluation will become the evidence that the medical and health institution refuses certain drugs to enter the medical and health institution
.
This may be the main reason why the guidelines emphasize the confidentiality of information related to comprehensive clinical evaluation
.
.
The relevant evidence of the clinical comprehensive evaluation will become the evidence that the medical and health institution refuses certain drugs to enter the medical and health institution
.
This may be the main reason why the guidelines emphasize the confidentiality of information related to comprehensive clinical evaluation
.
2.
The legal effect of the impact on drug market access
2. The legal effect of the impact on drug market access
The legal effect of the impact on drug market access
The "Guidelines for the Management of Comprehensive Clinical Evaluation of Drugs (Trial Version in 2021)" is a normative document issued by the Department of Drug Policy and Essential Drug System of the National Health Commission.
It does not belong to departmental regulations and is not legally mandatory
.
That is to say, the evidence information generated by the use of this guide has reference value, but it cannot be used to force drugs to withdraw from the drug market of a hospital based on this information
.
It does not belong to departmental regulations and is not legally mandatory
.
That is to say, the evidence information generated by the use of this guide has reference value, but it cannot be used to force drugs to withdraw from the drug market of a hospital based on this information
.
It is expected that medical and health institutions will also be very cautious when using comprehensive clinical evaluation of evidence information
.
However, it is certain that the clinical comprehensive evaluation evidence information will be the important reference information for the hospital to decide whether the drug can enter the hospital
.
.
However, it is certain that the clinical comprehensive evaluation evidence information will be the important reference information for the hospital to decide whether the drug can enter the hospital
.
3.
The main factors affecting the access to the pharmaceutical market
3. The main factors affecting the access to the pharmaceutical market
The main factors affecting the access to the pharmaceutical market
Compared with the provisions of the medical insurance catalog access policy documents, the evaluation dimensions of clinical comprehensive evaluation are more diverse, including safety, effectiveness, economy, innovation, suitability, and accessibility
.
Compared with single-dimensional evaluation, multi-criteria decision-making is the leading international health technology evaluation method
.
However, the difficulty is how to integrate multiple dimensions and what decision-making criteria are combined to arrive at a decision-making conclusion
.
.
Compared with single-dimensional evaluation, multi-criteria decision-making is the leading international health technology evaluation method
.
However, the difficulty is how to integrate multiple dimensions and what decision-making criteria are combined to arrive at a decision-making conclusion
.
One method is to set different weights for the six dimensions through expert consultation, and finally form a summary score to rank the drugs for clinical comprehensive evaluation, and then draw the conclusion of hospital market access based on a certain decision criterion
.
In the process of this operation, the transparency of weights and decision-making standards will determine the fairness and credibility of hospital drug market access, and even affect the supply of hospital drugs in the future
.
.
In the process of this operation, the transparency of weights and decision-making standards will determine the fairness and credibility of hospital drug market access, and even affect the supply of hospital drugs in the future
.
In short, comprehensive clinical evaluation is very important for medical and health institutions and pharmaceutical companies .
The transparency of relevant evidence production, evaluation process, and decision-making process will determine the effectiveness of comprehensive clinical evaluation information for hospital drug market access.
However, understanding comprehensive clinical evaluation is important for pharmaceutical companies.
Practitioners are very important, and they need to accumulate knowledge in relevant aspects early and assess the impact on their own drug market access
.
Enterprise Enterprise Enterprise Hospital Hospital Hospital The transparency of relevant evidence production, evaluation process, and decision-making process will determine the effectiveness of comprehensive clinical evaluation information for hospital drug market access.
However, understanding comprehensive clinical evaluation is important for pharmaceutical companies.
Practitioners are very important, and they need to accumulate knowledge in relevant aspects early and assess the impact on their own drug market access
.
